Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.66 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | YAP1 | P46937 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1558284 | 0.87 | GPR119 (0.49) | GPR119KMT2AALDH1A1MEN1ALOX15 | |
| SCHEMBL1577658 | 0.83 | GPR119 (0.71) | GPR119KMT2AALDH1A1MEN1ALOX15 | |
| SCHEMBL4287319 | 0.82 | GPR119 (0.61) | GPR119KMT2AALDH1A1MEN1ALOX15 | |
| SCHEMBL1664563 | 0.80 | GPR119 (1.00) | GPR119KMT2AALDH1A1MEN1ALOX15 | |
| SCHEMBL1118325 | 0.80 | GPR119 (0.74) | GPR119PRMT5KMT2AALDH1A1MEN1 | |
| SCHEMBL3488486 | 0.80 | GPR119 (0.71) | GPR119PRMT5KMT2AALDH1A1MEN1 | |
| SCHEMBL4281273 | 0.79 | GPR119 (0.65) | GPR119KMT2AALDH1A1MEN1ALOX15 | |
| SCHEMBL1448479 | 0.79 | GPR119 (0.77) | GPR119 | |
| SCHEMBL4773784 | 0.79 | GPR119 (0.64) | GPR119ALDH1A1TP53MAPTTDP1 | |
| SCHEMBL1577467 | 0.77 | GPR119 (0.53) | GPR119PRMT5TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184572-A1 | ARYL GPR119 AGONISTS AND USES THEREOF | METABOLEX, INC. | 2012-07-19 | — | — | US | disclosed |
| US-20120184572-A1 | ARYL GPR119 AGONISTS AND USES THEREOF | METABOLEX, INC. | 2012-07-19 | — | — | US | disclosed |
| WO-2012046792-A1 | GPR119 AGONIST | 日本ケミファ株式会社 (JP) | 2012-04-12 | — | — | WO | disclosed |
| US-20110294836-A1 | ARYL GPR119 AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110294836-A1 | ARYL GPR119 AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2010008739-A2 | ARYL GPR119 AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184572-A1 | ARYL GPR119 AGONISTS AND USES THEREOF | GPR119, GPR27, GPR65 | GPR119 1/4885PRMT5 3932/4885KMT2A 2289/4885 |
| US-20110294836-A1 | ARYL GPR119 AGONISTS AND USES THEREOF | GPR119, GPR27, GPR65 | GPR119 1/4885PRMT5 3932/4885KMT2A 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.